CCA
ANAB icon

Childress Capital Advisors’s AnaptysBio ANAB Stock Holding History

Childress Capital Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-188
Closed -$4K – 207
2020
Q4 		$4K Buy
+188
New +$4.57K ﹤0.01% 797

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Childress Capital Advisors's ANAB Position: Q1 2021 in Review

Childress Capital Advisors sold out of AnaptysBio (ANAB) in Q1 2021, closing a stake of 188 shares — an estimated $4K sold.

Childress Capital Advisors first reported a position in ANAB in Q4 2020 and held it in 1 quarter. The position peaked at $4K in Q4 2020. 122 funds tracked by Wall St. Rank hold ANAB as of Q1 2021.

  • Childress Capital Advisors reported no remaining AnaptysBio position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 188 AnaptysBio shares in Q1 2021, an estimated $4K.
  • Childress Capital Advisors first reported a position in AnaptysBio in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's AnaptysBio position peaked at $4K in Q4 2020.
  • 122 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.